Passage Bio, Inc. (PASG)
| Market Cap | 24.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.46M |
| Shares Out | 62.15M |
| EPS (ttm) | -1.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,989,878 |
| Open | 0.4000 |
| Previous Close | 0.3975 |
| Day's Range | 0.4000 - 0.4257 |
| 52-Week Range | 0.2570 - 1.3300 |
| Beta | 1.67 |
| Analysts | Strong Buy |
| Price Target | 7.67 (+1,813.2%) |
| Earnings Date | Aug 7, 2025 |
About PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment o... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PASG stock is "Strong Buy." The 12-month stock price target is $7.67, which is an increase of 1,813.20% from the latest price.
News
Passage Bio Announces 1-for-20 Reverse Stock Split
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients...
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, ...
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a ...
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history ...
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...
Passage Bio Welcomes Tom Kassberg to Board of Directors
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Fr...
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biothera...
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, May 14, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, March 04, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
PHILADELPHIA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (...